
    
      The primary objective of the study is to evaluate the continued efficacy of modafinil
      treatment, compared to placebo treatment, in children and adolescents with
      attention-deficit/hyperactivity disorder (ADHD) who are responders to modafinil treatment, as
      assessed by the change from baseline (in this current study) in the total score from the ADHD
      Rating Scale, Fourth Edition (ADHD-RS-IV) (Home Version) at endpoint (week 6 or last
      double-blind post-baseline visit).
    
  